ACRNaCT trial protocol: Efficacy of adjuvant chemotherapy in patients with clinical T3b/ T4, N+ rectal Cancer undergoing Neoadjuvant Chemoradiotherapy: A pathology-oriented, prospective, multicenter, randomized, open-label, parallel group clinical trial

The CAO/ARO/AIO-94 demonstrated that neoadjuvant chemoradiotherapy (CRT) could decrease the rate of local recurrence rather than distal metastases in advanced rectal cancer. Adjuvant chemotherapy (ACT) can eliminate micrometastasis, and render a better prognosis to rectal cancer.